𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid

✍ Scribed by Tatjana Stojakovic; Csilla Putz-Bankuti; Günter Fauler; Hubert Scharnagl; Martin Wagner; Vanessa Stadlbauer; Gerald Gurakuqi; Rudolf E. Stauber; Winfried März; Michael Trauner

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
207 KB
Volume
46
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis

Statin therapy may target both hypercholesterolemia and cholestasis in primary biliary cirrhosis (PBC). However, little is known about the efficacy and safety of statins in PBC. The aim of this single-center study was therefore to prospectively examine the effects of atorvastatin on serum markers of cholestasis, aminotransferases, and lipid and bile acid metabolism as well as inflammatory and immunological markers in patients with PBC. Fifteen patients with early-stage PBC and an incomplete biochemical response to ursodeoxycholic acid (UDCA) therapy (defined as alkaline phosphatase 1.5-fold above the upper limit of normal after 1 year) were treated with atorvastatin 10 mg/day, 20 mg/day, and 40 mg/day for 4 weeks, respectively. Serum levels of alkaline phosphatase increased during atorvastatin 20 mg and 40 mg (P < 0.05), whereas leucine aminopeptidase and ␥-glutamyltransferase remained unchanged. No statistical differences in overall serum ALT, AST, bilirubin, and IgM levels were observed. However, atorvastatin was discontinued in 1 out of 15 patients because of ALT 2-fold above baseline, and 2 patients showed ALT elevations 3-fold above the upper limit of normal at the end of the atorvastatin treatment period. Serum total cholesterol and low-density lipoprotein cholesterol levels decreased by 35% and 49%, respectively (P < 0.001). Precursors of cholesterol biosynthesis (lanosterol, desmosterol, lathosterol) showed a similar pattern. No changes in serum bile acid levels and composition were observed during treatment. Conclusion: Atorvastatin does not improve cholestasis in PBC patients with an incomplete biochemical response to UDCA but effectively reduces serum cholesterol levels.

📜 SIMILAR VOLUMES

Biochemical response to ursodeoxycholic
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
✍ Christophe Corpechot; Ludovico Abenavoli; Nabila Rabahi; Yves Chrétien; Tony And 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB 👁 1 views

Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. It has been recently proposed that an alkaline phosphatase (ALP) decline of more than 40% in baseline value or a normal level after 1 year of UDCA treatment (Barcelona criteria) could se

Comment on biochemical response to ursod
Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
✍ Lucy J. Walker; Julia Newton; David E. J. Jones; Margaret F. Bassendine 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

We read with interest the article by Corpechot et al. in a recent issue of HEPATOLOGY. 1 Corpechot et al. identify the absence of a biochemical response to ursodeoxycholic acid (UDCA) as an important predictive factor for death or liver transplantation in patients with primary biliary cirrhosis (PBC

Ursodeoxycholic acid inhibits eosinophil
Ursodeoxycholic acid inhibits eosinophil degranulation in patients with primary biliary cirrhosis
✍ Kiyoshi Yamazaki; Kazuyuki Suzuki; Atsushi Nakamura; Shunichi Sato; Keith D. Lin 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB 👁 1 views

Eosinophilia is a distinctive feature of primary biliary cirrhosis (PBC), especially in its early stages. Intriguingly, treatment with ursodeoxycholic acid (UDCA) ameliorates eosinophilia as well as liver tests in patients with PBC. It remains unknown, however, whether eosinophils in PBC patients ar

Oral budesonide in the treatment of pati
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
✍ Paul Angulo; Roberta A. Jorgensen; Jill C. Keach; E. Rolland Dickson; Coleman Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

Ursodeoxycholic acid (UDCA) is a safe and effective medical therapy for most patients with primary biliary cirrhosis (PBC). However, some patients show an incomplete response to UDCA therapy. Treatment with corticosteroids may be of benefit although at the expense of systemic side effects. Budesonid

A randomized trial comparing colchicine
A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis
✍ R E Poupon; P M Huet; R Poupon; A Bonnand; J T Van Nhieu; E S Zafrani 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB 👁 2 views

The efficacy of colchicine combined with ursodeoxycholic acid (UDCA) and UDCA alone in the treatment of patients with nonadvanced primary biliary cirrhosis (PBC) was evaluated in a 2-year controlled study. Seventy-four patients with PBC who had been treated previously with UDCA (at least 8 months) b